The role and importance of gene polymorphisms in the development of atherosclerosis

Interventional Medicine and Applied Science

Volumn 5, Issue 1, 2013, Pages 46-51

  Szabó, Gábor Viktor ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Atherosclerosis; ENOS G298T; MTHFR C677T; Polymorphism; TNF G308A

Indexed keywords

ANTIDIABETIC AGENT; ASPARAGINE; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; PROTEIN; PROTEIN MTHFR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; DNA EXTRACTION; EARLY DIAGNOSIS; GENE SEQUENCE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84879300879     PISSN: 20611617     EISSN: 20615094     Source Type: Journal    
DOI: 10.1556/IMAS.5.2013.1.10     Document Type: Article

References (35)

1. Szollár L (2005): Az atherosclerosis. In: Kóré lettan, ed. Szollár L, Semmelweis Kiadó, Budapest, pp. 304-328
2. Meskó É, Szollár L (1999): Az arteriosclerosis kórélettana. In: Belgyógyászati angiologia, eds Meskó É, Farsang Cs, Pécsvárady Zs, Medintel Könyvkiadó, Budapest, pp. 55-67
3. Hosszúfalusi N: A hyperglycaemia szerepe a diabetes mellitus késoi szövodményeinek kialakulásában. LAM 10(1), 40-48 (2000)
4. Jermendi Gy: Diabetes mellitus és az arterias é rbetegségek. Hippocrates 3(5), 319-314 (2001)
5. Nieszner É, Bárdos P, Baranyi É, Préda I: A diabetes mellitus cardiovascularis szövodmenyei és diagnózisuk. LAM 15(10), 722-729 (2005)
6. Lusis A: Atherosclerosis. Nature 407(14), 233-241 (2000)
7. Szalai Cs: Atherosclerosis. Genetikai alapok. Jegyzet 1-18 (2009)
8. Willerson J, Ridker P: Inflammation as a cardiovascular risk factor. Circulation 109, 2-10 (2004)
9. Blanke G, Ridker P: Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. Ital Heart J 2(11), 796-800 (2001)
10. Corti R, Hutter R, Badimon JJ, Fuster V: Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 17(1), 35-44 (2004)
11. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105, 1135-1143 (2002)
12. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 340, 115-126 (1999)
13. Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 109, 27-3 (2004)
14. De Graba TJ: Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation. Stroke 35, 2712-2719 (2004)
15. Giese N, Marijianowski M, McCook O, Hancock A, Ramakrishnan V, Fretto L, Chen C, Kelly A, Koziol J, Wilcox J, Hanson S: The role of alpha and beta platelet-derived growth factor in the vascular response to injury in nonhuman primates. Atheroscler Thromb Vasc Biol 19, 900-909 (1999)
16. Jaeger BR, Labarrrere CA: Fibrinogen und atherothrombose: vulnerable plaque oder vulnerabler patient? Herz 28, 530-538 (2003)
17. Ridker P, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E: Elevation of tumor necrosis factor-alfa, and increased risk of recurrent coronary events after myocardial infarction. Circulation 101, 2149-2153 (2000)
18. Gardner M, Palmer J, Manrique C, Lestra G, Gardner DW, Sower JR: Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes. J Cardiometab Syndr 4(2), 96-101 (2009)
19. Geisler T, Bhatt DL: The role of inflammation in atherosclerosis: current and future strategies of medical treatment. Med Sci Monit 10(12), 308-316 (2004)
20. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D: MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group: prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 363, 1491-1502 (2004)
21. Colombo MG, Paradossi U, Andreassi MG, Botto N, Manfredi S, Masetti S, Biagini A, Clerico A: Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 49, 389-395 (2003)
22. Hingorani A, Liang Ch, Fatibene J, Monteith S, Parsons A, Haydock S, Hopper R, Stephens N: a common variant of the endothelial nitric oxid synthase (Glu298-Asp) is a major risk factor for coronary artery disease in the UK. Circulation 100, 1515-1520 (1999)
23. Rossi GP, Cesari M, Zanchetta M, Colonna S, Maiolino G, Pedon L, Cavallin M, Maiolino P, Pessina AC: The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol, 41, 930-937 (2003)
24. Yang Z, Ming X: Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 4(1), 53-65 (2006)
25. Marroni AS, Metzger IF, Souza-Costa DC, Nagassaki S, Sandrim VC, Correa RX, Rios-Santos F, Tanus-Santos JE: Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. Nitric Oxide 12, 177-182 (2005)
26. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH: Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332, 286-291 (1995)
27. Bova I, Chapman J, Sylantiev C, Korczyn AD, Bornstein NM: The A677V methylenetetrahydrofolate reductase gene polymorphism and carotid atherosclerosis. Stroke 30, 2180-2182 (1999)
28. Mazza A, Giugliano D, Motti C, Cortese C, Andreotti F, Marra G, Nulli A: Glycemia, MTHFR genotype and low homocysteine in uncomplicated type 2 diabetic patients. Atherosclerosis 149, 223-224 (2000)
29. Elkind MS, Cheng J, Boden-Albala B, Rundek T, Thomas J, Chen H, Rabbani LE, Sacco RL: Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke 33, 31-38 (2002)
30. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC: Tumor necrosis factor-a reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol 293, 1115-1121 (2007)
31. Monraats PS, Pires N M M, Schepers A, Agema W, Boesten L, Vries M, Zwinderman A, De Maat M, Doevendans P, Winter R, Tio R, Waltenberger J, Hart L, Frants R, Quax P, Vlijmen B, Havekes L, Laarse A, Wall E, Jukema W: Tumor necrosis factor-a plays an important role in restenosis development. FASEB J, 19, 1998-2004 (2005)
32. Fernandez-Real JM, Gutierrez C, Ricart W, Casamitjana R, Fernandez-Castaner M, Vendrell J, Richart C, Soler J: The TNF-alpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 46(9), 2096-2098 (1997)
33. Szél Á, Merkely B, Hüttl K, Gál J, Nemes B, Komócsi A: Statement of ethical publishing and scientific authorship. Int Med Appl Sci 2, 101-102 (2010)
34. Szabó GV, Kunstár A, Acsády Gy: Methylentetrahydrofolate reductase and nitric oxide synthase polymorphism in patients with atherosclerosis and diabetes. Pathol Oncol Res 15, 631-637 (2009)
35. Szabó GV, Acsády Gy: Tumornecrosis-factor-α 308 GA Polymorphism in atherosclerotic patients. Pathol Oncol Res 17, 853-857 (2011)